CARLSBAD, Calif., Nov. 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals announces the following webcast:
What: Isis Pharmaceuticals’ analyst/investor presentation highlighting new Phase 2 clinical data from ISIS 301012 studies planned for release at the American Heart Association Scientific Sessions. ISIS 301012 is the Company’s cholesterol-lowering drug targeting apoB-100. When: November 13, 2006 @ 8:00 AM Eastern Where: www.isispharm.com How: Live over the Internet -- select the link on Isis’ home page at the address above. Contact: Kate Corcoran, Ph.D. Vice President, Corporate Development 760-603-2712
If you are unable to participate during the live webcast, the presentation will be available for replay at www.isispharm.com.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world’s first antisense drug and has 14 drugs in development. Isis’ drug development programs are aimed at treating cardiovascular, metabolic and inflammatory diseases. Isis’ partners are focused in disease areas such as ocular, viral and neurodegenerative diseases, and cancer. In its Ibis Biosciences division, Isis is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of approximately 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.
Isis Pharmaceuticals
CONTACT: Kate Corcoran, Ph.D., Vice President, Corporate Development ofIsis Pharmaceuticals, +1-760-603-2712
Web site: http://www.isispharm.com/
